Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 15;6(6):e12776.
doi: 10.1002/rth2.12776. eCollection 2022 Aug.

Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations

Linda Nab  1 , Rolf H H Groenwold  1   2 , Frederikus A Klok  3 , Soerajja Bhoelan  4 , Marieke J H A Kruip  5 , Suzanne C Cannegieter  1   3
Affiliations

Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations

Linda Nab et al. Res Pract Thromb Haemost. .

Abstract

Background: Coagulation abnormalities and coagulopathy are recognized as consequences of severe acute respiratory syndrome coronavirus 2 infection and the resulting coronavirus disease 2019 (COVID-19). Specifically, venous thromboembolism (VTE) has been reported as a frequent complication. By May 27, 2021, at least 93 original studies and 25 meta-analyses investigating VTE incidence in patients with COVID-19 had been published, showing large heterogeneity in reported VTE incidence ranging from 0% to 85%. This large variation complicates interpretation of individual study results as well as comparisons across studies, for example, to investigate changes in incidence over time, compare subgroups, and perform meta-analyses.

Objectives: This study sets out to provide an overview of sources of heterogeneity in VTE incidence studies in patients with COVID-19, illustrated using examples.

Methods: The original studies of three meta-analyses were screened and a list of sources of heterogeneity that may explain observed heterogeneity across studies was composed.

Results: The sources of heterogeneity in VTE incidence were classified as clinical sources and methodologic sources. Clinical sources of heterogeneity include differences between studies regarding patient characteristics that affect baseline VTE risk and protocols used for VTE testing. Methodologic sources of heterogeneity include differences in VTE inclusion types, data quality, and the methods used for data analysis.

Conclusions: To appreciate reported estimates of VTE incidence in patients with COVID-19 in relation to its etiology, prevention, and treatment, researchers should unambiguously report about possible clinical and methodological sources of heterogeneity in those estimates. This article provides suggestions for that.

Keywords: COVID‐19; SARS‐CoV‐2; incidence; meta‐analysis; venous thromboembolism.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Clinical sources of heterogeneity in venous thromboembolism incidence studies that may explain observed heterogeneity across studies. Abbreviations: ICU, intensive care unit; OAC, oral anticoagulation; VTE, venous thromboembolism
FIGURE 2
FIGURE 2
Methodological sources of heterogeneity in venous thromboembolism incidence studies that may explain observed heterogeneity across studies. Abbreviations: CTPA, computed tomography pulmonary angiogram; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID‐19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9(6):622‐642. - PMC - PubMed
    1. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID‐19: an updated analysis. Thromb Res. 2020;191:148‐150. - PMC - PubMed
    1. Al‐Ani F, Chehade S, Lazo‐Langner A. Thrombosis risk associated with COVID‐19 infection. A scoping review. Thromb Res. 2020;192:152‐160. - PMC - PubMed
    1. Birocchi S, Manzoni M, Podda GM, Casazza G, Cattaneo M. High rates of pulmonary artery occlusions in COVID‐19. A meta‐analysis. Eur J Clin Invest. 2021;51(1):e13433. doi:10.1111/eci.13433 - DOI - PMC - PubMed
    1. Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID‐19: a systematic review and meta‐analysis. Vasc Med. 2021;26(4):415‐425. doi:10.1177/1358863X21995566 - DOI - PMC - PubMed